View Clinical Trial (Medical Research Study)

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis - NCT00570752-10029(Clinical Trial 194122)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  New York
State:  
NY
Zip Code: 10029
Conditions: Vascular Diseases
Purpose: The purpose of the study is to determine whether a p38 kinase inhibitor reduces inflammation in atherosclerotic plaque
Study summary:
Criteria: Inclusion Criteria: - History of documented atherosclerosis - LDL between 70 and 130 mg/dL - Patients receiving stable low- to moderate-dose statin - BMI 18-37 kg/m² - Must be able to swallow tablets - Must be able to medically tolerate the procedures, contrast medium, and medications involved Exclusion Criteria: - Statin intolerance - Renal impairment (serum creatinine > 1.5 mg/dL) - History of chronic viral hepatitis or other liver dysfunction - Major infection requiring hospitalization or receipt of IV antibiotics due to an infection within 2 months prior to initiation of study treatment
Study is available at: Mount Sinai School Of Medicine Imaging Science Laboratories
New York, NY 10029
United States

Primary Contact:
For participation information at a USA site use a phone number below. For site information outside the USA please email:
Email: Clinical.Trials@bms.com
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.